Cargando…

Validation of Minnesota acute graft-versus-host disease Risk Score

Using multicenter data, we developed a novel acute graft-versus-host disease Risk Score which more accurately predicts response to steroid treatment, survival and transplant related mortality than other published risk scores based upon clinical grading criteria.(1) To validate this Risk Score in a c...

Descripción completa

Detalles Bibliográficos
Autores principales:	MacMillan, Margaret L., DeFor, Todd E., Holtan, Shernan G., Rashidi, Armin, Blazar, Bruce R., Weisdorf, Daniel J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012472/ https://www.ncbi.nlm.nih.gov/pubmed/31320554 http://dx.doi.org/10.3324/haematol.2019.220970

Ejemplares similares

High cutaneous amphiregulin expression predicts fatal acute graft‐versus‐host disease
por: Schultz, Brittney, et al.
Publicado: (2022)

Donor and Recipient Plasma Follistatin Levels are Associated with Acute Graft-versus-Host Disease in Blood and Marrow Transplant Clinical Trials Network 0402
por: Turcotte, Lucie M., et al.
Publicado: (2017)

Higher Therapeutic Cyclosporine Levels Early Post-Transplantation Reduces Risks of Acute Graft-Versus-Host Disease and Improves Survival
por: Rogosheske, John R., et al.
Publicado: (2013)

Graft-versus-host disease: teaching old drugs new tricks at less cost
por: Farhan, Shatha, et al.
Publicado: (2023)

Prediction of outcomes after second-line treatment for acute graft-versus-host disease
por: Vo, Phuong, et al.
Publicado: (2022)

High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group
por: El Jurdi, Najla, et al.
Publicado: (2021)

Life-Threatening Hypertriglyceridemia in a Patient on Ruxolitinib and Sirolimus for Chronic Graft-versus-Host Disease
por: Watson, Allison P., et al.
Publicado: (2018)

Minnesota plant life
por: MacMillan, Conway, 1867-1929
Publicado: (1899)

Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes
por: Herzog, Shannon, et al.
Publicado: (2023)

Altered microbiota-host metabolic cross talk preceding neutropenic fever in patients with acute leukemia
por: Rashidi, Armin, et al.
Publicado: (2021)

Dysbiosis patterns during re-induction/salvage versus induction chemotherapy for acute leukemia
por: Rashidi, Armin, et al.
Publicado: (2019)

Minnesota acute graft-versus-host disease risk score predicts survival at onset of graft-versus-host disease after post-transplant cyclophosphamide prophylaxis
por: Ardizzoia, Federica, et al.
Publicado: (2022)

Gut microbiota response to antibiotics is personalized and depends on baseline microbiota
por: Rashidi, Armin, et al.
Publicado: (2021)

Effect of COVID-19 precautions on the gut microbiota and nosocomial infections
por: Rashidi, Armin, et al.
Publicado: (2021)

Loss of microbiota-derived protective metabolites after neutropenic fever
por: Rashidi, Armin, et al.
Publicado: (2022)

Compilation of longitudinal gut microbiome, serum metabolome, and clinical data in acute myeloid leukemia
por: Rashidi, Armin, et al.
Publicado: (2022)

Lasting shift in the gut microbiota in patients with acute myeloid leukemia
por: Rashidi, Armin, et al.
Publicado: (2022)

Disease progression, hospital readmissions, and clinical outcomes for patients with steroid-refractory acute graft-versus-host disease: A multicenter, retrospective study
por: Holtan, Shernan G., et al.
Publicado: (2022)

Regulatory T Cell Therapy of Graft-versus-Host Disease: Advances and Challenges
por: Hefazi, Mehrdad, et al.
Publicado: (2021)

Vancomycin-resistance gene cluster, vanC, in the gut microbiome of acute leukemia patients undergoing intensive chemotherapy
por: Rashidi, Armin, et al.
Publicado: (2019)

Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in GVHD Risk Without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate
por: El Jurdi, Najla, et al.
Publicado: (2023)

Validated graft-specific biomarkers identify patients at risk for chronic graft-versus-host disease and death
por: Logan, Brent R., et al.
Publicado: (2023)

Polymorphisms in the Base Excision Repair Pathway and Graft-versus-Host Disease
por: Arora, Mukta, et al.
Publicado: (2010)

Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated
por: Nikiforow, Sarah, et al.
Publicado: (2018)

75200 Fecal Microbiota Transplantation to Prevent Infections in Patients with Acute Myeloid Leukemia: A Double-Blind Randomized Placebo-Controlled Phase 2 Clinical Trial
por: Ebadi, Armin Rashidiryam, et al.
Publicado: (2021)

Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
por: Holtan, Shernan G., et al.
Publicado: (2023)

Comparative analysis of antibiotic exposure association with clinical outcomes of chemotherapy versus immunotherapy across three tumour types
por: Kulkarni, Amit A, et al.
Publicado: (2020)

Early E. casseliflavus gut colonization and outcomes of allogeneic hematopoietic cell transplantation
por: Rashidi, Armin, et al.
Publicado: (2019)

ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease
por: Jagasia, Madan, et al.
Publicado: (2021)

Solid Organ Transplant Graft-Versus-Host Disease in a Kidney/Pancreas Transplant Patient: Use of Chimerism Testing and a Rare Presentation of Cutaneous GVHD
por: Goyal, Amrita, et al.
Publicado: (2022)

Effects of MicroRNA on Regulatory T Cells and Implications for Adoptive Cellular Therapy to Ameliorate Graft-versus-Host Disease
por: Hippen, Keli L., et al.
Publicado: (2018)

Emerging translational strategies and challenges for enhancing regulatory T cell therapy for graft-versus-host disease
por: Hippen, Keli L., et al.
Publicado: (2022)

Diffuse alveolar hemorrhage is most often fatal and is affected by graft source, conditioning regimen toxicity, and engraftment kinetics
por: Keklik, Fatma, et al.
Publicado: (2018)

Achievement of Tolerance Induction to Prevent Acute Graft-vs.-Host Disease
por: Thangavelu, Govindarajan, et al.
Publicado: (2019)

Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease
por: Le, Hongnga T., et al.
Publicado: (2020)

Cytolytic CD4(+) and CD8(+) Regulatory T-Cells and Implications for Developing Immunotherapies to Combat Graft-Versus-Host Disease
por: Bolivar-Wagers, Sara, et al.
Publicado: (2022)

Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease
por: Mohamed, Fathima A., et al.
Publicado: (2021)

Mechanisms by Which Obesity Promotes Acute Graft-Versus-Host Disease in Mice
por: Khuat, Lam T., et al.
Publicado: (2021)

Fecal β-glucuronidase activity differs between hematopoietic cell and kidney transplantation and a possible mechanism for disparate dose requirements
por: Khan, Mohammad Haneef, et al.
Publicado: (2022)

The lichens of Minnesota /
por: Fink, Bruce, 1861-1927
Publicado: (1910)

Cannot write session to /tmp/vufind_sessions/sess_7694vthckvs2heoigsavjj1ioo